Compositions and methods for inhibiting TGF-β

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S303000, C544S284000, C546S119000

Reexamination Certificate

active

10795538

ABSTRACT:
This invention provides compounds that are useful for treating patients having a TGF-β-mediated disease, particularly an ALK5-mediated disease. The compounds are represented by formula I:wherein: a-b is CH2CH2, CH2CH2CH2, CH═CH, CH═N, or N═CH; Z is N or C—F; and G is C1-6aliphatic or a phenyl, naphthyl, or 5-6 membered heteroaryl ring.

REFERENCES:
patent: 5223501 (1993-06-01), Chakravarty et al.
patent: 5571828 (1996-11-01), Strupczewski et al.
patent: 6184226 (2001-02-01), Chakravarty et al.
patent: 6225318 (2001-05-01), Sobolov-Jaynes et al.
patent: 6277989 (2001-08-01), Chakravarty et al.
patent: 6476031 (2002-11-01), Chakravarty et al.
patent: 2002/0161010 (2002-10-01), Chakravarty et al.
patent: WO 00/12497 (2000-03-01), None
patent: WO 03/097615 (2003-11-01), None
patent: WO 04/010929 (2004-02-01), None
Chemical Abstracts Registry File, Registry No. 685134-74-1 (see attached).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Compositions and methods for inhibiting TGF-β does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for inhibiting TGF-β, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting TGF-β will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3729746

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.